X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with SHASUN PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs SHASUN PHARMA - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA SHASUN PHARMA GSK PHARMA/
SHASUN PHARMA
 
P/E (TTM) x 64.0 123.9 51.6% View Chart
P/BV x 10.3 8.5 120.4% View Chart
Dividend Yield % 1.2 0.2 528.4%  

Financials

 GSK PHARMA   SHASUN PHARMA
EQUITY SHARE DATA
    GSK PHARMA
Mar-17
SHASUN PHARMA
Mar-14
GSK PHARMA/
SHASUN PHARMA
5-Yr Chart
Click to enlarge
High Rs3,83894 4,074.3%   
Low Rs2,63746 5,782.9%   
Sales per share (Unadj.) Rs354.2214.2 165.4%  
Earnings per share (Unadj.) Rs39.85.3 745.2%  
Cash flow per share (Unadj.) Rs42.915.8 271.0%  
Dividends per share (Unadj.) Rs30.001.00 3,000.0%  
Dividend yield (eoy) %0.91.4 64.8%  
Book value per share (Unadj.) Rs236.953.3 444.2%  
Shares outstanding (eoy) m84.7056.62 149.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x9.10.3 2,800.8%   
Avg P/E ratio x81.413.1 621.5%  
P/CF ratio (eoy) x75.54.4 1,709.2%  
Price / Book Value ratio x13.71.3 1,042.7%  
Dividend payout %75.418.7 402.6%   
Avg Mkt Cap Rs m274,2163,958 6,928.6%   
No. of employees `0004.7NA-   
Total wages/salary Rs m4,8302,164 223.2%   
Avg. sales/employee Rs Th6,387.0NM-  
Avg. wages/employee Rs Th1,028.3NM-  
Avg. net profit/employee Rs Th717.1NM-  
INCOME DATA
Net Sales Rs m30,00012,127 247.4%  
Other income Rs m728229 317.5%   
Total revenues Rs m30,72812,356 248.7%   
Gross profit Rs m4,1901,009 415.2%  
Depreciation Rs m263594 44.3%   
Interest Rs m0415 0.0%   
Profit before tax Rs m4,655230 2,026.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00 0.0%   
Extraordinary Inc (Exp) Rs m4570-   
Tax Rs m1,744-73 -2,398.2%   
Profit after tax Rs m3,368302 1,114.8%  
Gross profit margin %14.08.3 167.8%  
Effective tax rate %37.5-31.7 -118.3%   
Net profit margin %11.22.5 450.6%  
BALANCE SHEET DATA
Current assets Rs m16,7426,884 243.2%   
Current liabilities Rs m7,2028,456 85.2%   
Net working cap to sales %31.8-13.0 -245.4%  
Current ratio x2.30.8 285.5%  
Inventory Days Days5262 84.1%  
Debtors Days Days21108 19.3%  
Net fixed assets Rs m8,6354,970 173.7%   
Share capital Rs m847113 747.6%   
"Free" reserves Rs m19,2222,875 668.6%   
Net worth Rs m20,0693,020 664.5%   
Long term debt Rs m101,817 0.6%   
Total assets Rs m30,03813,347 225.1%  
Interest coverage xNM1.6-  
Debt to equity ratio x00.6 0.1%  
Sales to assets ratio x1.00.9 109.9%   
Return on assets %11.25.4 208.7%  
Return on equity %16.810.0 167.8%  
Return on capital %25.513.3 191.1%  
Exports to sales %046.4 0.0%   
Imports to sales %014.2 0.0%   
Exports (fob) Rs mNA5,622 0.0%   
Imports (cif) Rs mNA1,728 0.0%   
Fx inflow Rs m5285,843 9.0%   
Fx outflow Rs m7,1932,173 331.0%   
Net fx Rs m-6,6653,669 -181.6%   
CASH FLOW
From Operations Rs m2,360398 593.6%  
From Investments Rs m3,008-1,635 -184.0%  
From Financial Activity Rs m-5,1081,309 -390.3%  
Net Cashflow Rs m26071 365.6%  

Share Holding

Indian Promoters % 0.0 39.2 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 3.6 283.3%  
FIIs % 23.8 17.6 135.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 39.6 38.9%  
Shareholders   102,036 20,750 491.7%  
Pledged promoter(s) holding % 0.0 12.3 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   NATCO PHARMA  PLETHICO PHARMA  WOCKHARDT LTD.  TORRENT PHARMA  PANACEA BIOTECH  

Compare GSK PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Start to the Week; PSU & Metal Stocks Fall(Closing)

Indian share markets continued to witness selling pressure in the afternoon session as benchmark Sensex slipped below the 34,000-mark.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Feb 19, 2018 03:37 PM

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA - FDC LTD. COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS